XENE Q3 2020 Earnings — Xenon Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

XENEXenon Pharmaceuticals Inc.

$5B

Q3 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$7M+87.3% YoY

Gross Profit

$7M100.0% margin

Operating Income

-$10M-148.0% margin

Net Income

-$9M-135.1% margin

EPS (Diluted)

$-0.25

QoQ Revenue Growth

-51.0%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$13M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$199M

Total Liabilities

$17M

Stockholders' Equity

$182M

Cash & Equivalents

$15M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$7M	$4M	+87.3%
Gross Profit	$7M	-$6M	+204.8%
Operating Income	-$10M	-$9M	-8.4%
Net Income	-$9M	-$9M	+0.2%

Revenue Segments

License And Service

$7M100%